Drug intelligence / Profile preview

RESP2000

Development stage: Preclinical
Lead developer: Respiratorius
Modality: Small Molecules
Administration: Inhalation

Overview

RESP2000 is a preclinical-stage small molecule drug candidate being developed by Respiratorius for the treatment of chronic obstructive pulmonary disease (COPD) and severe asthma. It belongs to the RESP series of compounds, which are designed as novel bronchodilators that relax airway smooth muscle through a mechanism of action distinct from current standard-of-care treatments, such as beta-2 agonists and muscarinic antagonists. The program aims to address the needs of patients with obstructive lung diseases who do not achieve adequate symptom control with existing therapies.

Beyond the preview

Go deeper on RESP2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RESP2000.

Explore the full profile